Key Takeaways
- • PayPal founder Peter Thiel co-leads $10 million Series B funding round for ChemomAb, a Tel Aviv-based biopharmaceutical company developing monoclonal antibodies for inflammatory and fibrotic diseases, alongside OrbiMed Advisors' Israel unit.
- • ChemomAb's lead candidate targets non-alcoholic fatty liver disease (NASH), a monoclonal antibody in Phase I clinical trials designed to inhibit a key protein driving fibrotic and inflammatory mechanisms; proceeds will fund clinical advancement and efficacy/safety studies in NASH patients.
- • Syndicate includes SBI Japan-Israel Innovation Fund and Milestone Venture, reflecting diversified international investor participation; this marks ChemomAb's second funding round following an earlier $5 million raise from OrbiMed Israel and private investors.
- • Thiel's investment signals continued venture capital interest in Israeli biotech, particularly in therapeutic antibody development and liver disease treatment, an area with significant clinical and commercial potential.
Summary
Peter Thiel, PayPal co-founder and prominent technology investor, has co-led a $10 million Series B financing round for ChemomAb, an Israeli biopharmaceutical startup headquartered in Tel Aviv. The funding was jointly led by Thiel and the Israel unit of OrbiMed Advisors LLC, a New York-based venture capital firm with established healthcare investment focus. Additional capital came from the SBI Japan-Israel Innovation Fund and Milestone Venture Partners, demonstrating participation from both Asian and Western investor bases.
ChemomAb is developing monoclonal antibody therapeutics targeting inflammatory and fibrotic diseases, with its lead candidate currently in Phase I clinical trials in Israel. The compound functions as a monoclonal antibody designed to neutralize a key protein implicated in fibrotic and inflammatory disease progression. The company intends to deploy the new capital to accelerate its clinical development program while evaluating the drug candidate's efficacy and safety profile in patients with non-alcoholic fatty liver disease (NASH), a liver condition clinically similar to alcoholic liver disease but occurring in patients with minimal or no alcohol consumption.
According to ChemomAb CEO Adi Mor, the funding will support advancement of the company's clinical program and patient studies. This represents ChemomAb's second institutional funding round; the company previously raised $5 million from OrbiMed Israel and private investors, demonstrating investor confidence in the therapeutic approach. The syndicate composition—spanning North American, European, Japanese, and Israeli capital sources—reflects broad institutional recognition of both ChemomAb's technology platform and the expanding market opportunity in liver disease therapeutics.
The investment underscores Thiel's ongoing engagement with the Israeli technology and life sciences ecosystem and signals continued venture capital confidence in monoclonal antibody development as a therapeutic modality for treatment-resistant liver and fibrotic conditions.
ChemomAb is developing monoclonal antibody therapeutics targeting inflammatory and fibrotic diseases, with its lead candidate currently in Phase I clinical trials in Israel. The compound functions as a monoclonal antibody designed to neutralize a key protein implicated in fibrotic and inflammatory disease progression. The company intends to deploy the new capital to accelerate its clinical development program while evaluating the drug candidate's efficacy and safety profile in patients with non-alcoholic fatty liver disease (NASH), a liver condition clinically similar to alcoholic liver disease but occurring in patients with minimal or no alcohol consumption.
According to ChemomAb CEO Adi Mor, the funding will support advancement of the company's clinical program and patient studies. This represents ChemomAb's second institutional funding round; the company previously raised $5 million from OrbiMed Israel and private investors, demonstrating investor confidence in the therapeutic approach. The syndicate composition—spanning North American, European, Japanese, and Israeli capital sources—reflects broad institutional recognition of both ChemomAb's technology platform and the expanding market opportunity in liver disease therapeutics.
The investment underscores Thiel's ongoing engagement with the Israeli technology and life sciences ecosystem and signals continued venture capital confidence in monoclonal antibody development as a therapeutic modality for treatment-resistant liver and fibrotic conditions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.